In the past couple of weeks several insiders have been making
buys into their companies as their prices drop to or near their
52-week low prices. It is interesting to look at insider buys
while the prices of the company are sitting at lows because they
can signify a turnaround in the company.
As Peter Lynch says about insider buying, "Insiders might sell
their shares for any number of reasons, but they buy them for
only one: they think the price will rise." The following
companies reported insider buys coming from several different
insiders during the past two weeks.
ZaZa Energy (
As ZaZa Energy sits near its 52-week low price of $1.19,
several insiders made buys
into the company. Four insiders have made buys as the price sits
near its low.
Chief Accounting Officer Paul Jansen added 5,000 shares at an
average price of $1.40. This cost him $7,000. He now owns 58,409
shares of ZaZa. Since his buy the price per share has increased
Director Todd Brooks bought 50,000 at $1.44 per share. This cost
the director a total of $72,000. He now owns over 22 million
shares of ZaZa Energy. Since his buy the price per share has
CCO and General Counsel Shelby Gaille bought a total of 14,600
shares at an average price of $1.38. This buy cost a total of
$20,148. Since this buy the price per share has increased 2.17%.
Gaille now owns at least 408,458 shares of ZaZa.
CFO Ian Fay bought 30,000 shares of company stock at an average
price of $1.48. This transaction cost Fay $44,400. The CFO now
owns over 1 million shares of ZaZa Energy. Since his buy, the
price has decreased 4.73%.
ZaZa Energy is a privately held independent exploration and
production company focused on the exploration and development of
exploration and development of unconventional onshore oil and gas
resources in the U.S. Its operations are primarily concentrated
in South Texas.
on ZaZa Energy reports:
� The per share revenue has been in decline for the
past five years.
� The cash flow from operations has severe divergence
from the reported net income.
ZaZa Energy has a market cap of $140.5 million; its shares were
traded at around $1.40 with a P/E ratio of 2.50 and a P/S ratio
There are currently no gurus that hold stake in ZaZa Energy.
TOR Minerals (
Five insiders made buys into the company this past week as the
price sits near the 52-week low price of $10.57.
Director David Hartman bought 5,133 shares at an average price of
$9.62 per share. This cost him $49,379. Since his buy, the price
per share has increased 19.02%. He holds on to at least 618,313
shares of TOR Minerals.
Director Douglas Hartman, Executive VP of Sales and Marketing
Mark Schomp, President and CEO Olaf Karasch and Director Bernard
Paulson all bought shares at a price of $11.05. The insiders
bought a combined total of 18,708 shares. These buys cost them a
combined total of $206,723.
TOR Minerals is a global specialty chemical company engaged in
the business of manufacturing and marketing mineral products for
use as pigments, pigment extenders, functional fillers and flame
retardants used in the manufacture of paints, coatings, plastics
The analysis on TOR Minerals states:
� The company has issued $4.36 million of debt in the
past three years.
� The P/B ratio is close to a two-year low of 0.81.
� The P/S ratio is close to a two-year low of 0.66.
If you use Peter Lynch's method of valuation, you can see in the
chart below that TOR Minerals is currently undervalued.
TOR Minerals has a market cap of $34.6 million; its shares were
traded around $11.45 with a P/E ratio of 10.50 and a P/S ratio of
LivePerson reported five insider buys last week coming from four
different insiders. These buys come as the price drops down to a
Executive VP of Global Sales and Marketing Erica Schultz bought
15,000 shares at an average price of $8.95 per share. This cost
her $134,250. Since her buy, the price per share has increased
Director William Wesemann made two different buys, adding a total
of 30,000 shares of LivePerson stock. These shares traded at an
average price of $8.67 per share. This cost the director
$260,100. He now holds on to at least 60,000 shares of
CFO Daniel Murphy bought 4,350 shares at $8.52 per share. This
cost the CFO a total of $37,062. Since his buy the price per
share of the stock has increased 9.86%.
CEO Robert Locascio added the most to his stake by buying an
additional 35,640 shares of the company's stock. The shares
traded at $8.56 for a total transaction amount of $305,078. He
now holds nearly 5 million shares of his company's stock. Since
his buy, the price per share has increased 9.35%.
These insider buys mark the first insider transactions of 2013 as
well as the first insider buys since November 2010.
LivePerson provides online engagement solutions that facilitate
real-time assistance and expert advice. The company connects
businesses and independent service providers with consumers
seeking help on the Internet. LivePerson's hosted software
platform creates more relevant, compelling and personalized
The analysis on LivePerson reports:
� The company has no debt
� The price is close to a 2-year low of $8.39.
� The P/B ratio is close to a 3-year low of 2.81.
LivePerson has a market cap of $518.3 million; its shares were
traded at around $9.36 with a P/E ratio of 178.00 and P/S ratio
Ron Baron currently holds 1,317,077 shares representing 0.1% of
his total portfolio.
Cyclacel Pharmaceuticals (
Cyclacel Pharmaceuticals reported three insider buys in the past
President and CEO Spiro Rombotis bought 100,000 shares of the
company at $3.00 per share. This cost him $300,000. Since the
CEO's buy the price per share has increased 10.67%. Rombotis now
holds on to at least 241,416 shares of the company's stock.
Executive VP of Finance, CFO and COO Paul McBarron bought 12,948
shares of Cyclacel at $3.03 per share. This buy cost the CFO a
total of $39,239. Since his buy, the price has jumped 9.57%. He
now holds on to at least 70,096.
Director Lloyd Sems bought 33,333 shares of company stock last
week. The shares traded at $3.00 for a total transaction amount
costing the director $99,999. Since his buy the price per share
has gone up 10.67%.
These transactions mark the first insider transactions for the
company since December 2011.
Cyclacel Pharmaceuticals is a development-stage biopharmaceutical
company dedicated to the development and commercialization of
novel, mechanism-targeted drugs to treat human cancers and other
serious diseases. The company's strategy is to build a
diversified biopharmaceutical business focused in hematology and
oncology based on a development pipeline of novel drug
The analysis on Cyclacel Pharmaceuticals reports:
� The per share revenue has been in decline for the
past five years.
� The operating margin has also been in a five year
decline. The average rate of decline per year is 7.4%.
� The company has no debt.
� The company's price is nearing a three-year low of
Cyclacel Pharmaceuticals has a market cap of $37.2 million; its
shares were traded at around $3.33 with a P/S ratio of 104.70.
Wilbur Ross currently holds 116,316 shares of Cyclacel,
representing 0.06% of his total portfolio.
You can view all insider buys at 52- week lows here.About
GuruFocus: GuruFocus.com tracks the stocks picks and portfolio
holdings of the world's best investors. This value investing site
offers stock screeners and valuation tools. And publishes daily
articles tracking the latest moves of the world's best investors.
GuruFocus also provides promising stock ideas in 3 monthly
newsletters sent to